EGFR and lung adenocarcinoma: In this study, we had successfully developed and validated radiomics nomograms based on clinical characteristics and MRI to predict the short-term efficacy and iPFS of third-generation EGFR-TKIs, including osimertinib, almonertinib and furmonertinib, for lung adenocarcinoma patients with EGFR-mutated brain metastases.